Head and Neck Cancer Metastases
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".
Deadline for manuscript submissions: 1 February 2025 | Viewed by 3712
Special Issue Editors
Interests: head and neck cancer
Special Issues, Collections and Topics in MDPI journals
Interests: insulin resistance; cell biology; animal physiology; insulin signaling; aging; molecular biology; metabolism; fat; adipose tissue; quantitative PCR
Special Issue Information
Dear Colleagues,
Squamous carcinoma of head and neck (HNSCC) arising from the mucosa of the common part of the upper respiratory and digestive systems is the 6th most common malignancy in the world.
The most important risk factors for HNSCC development are tobacco use and extensive alcohol consumption. Moreover, infection with oncogenic types of human papillomavirus (HPV) has also been identified as a significant risk factor for a particular subset of HNSCC : tumors arising from the oropharynx. To date, head and neck oncology can offer a plethora of treatment modalities, including surgical resection with reconstructive options, radiotherapy (including proton therapy), conventional and targeted systemic treatment, and also, as of late, immunotherapy. The success rates of treatments can vary significantly between particular patients, but despite great advances in available treatment modalities and increasing amount of information regarding tumor biology, the overall survival rate in this disease remains relatively low. The main reasons for failure in HNSCC treatment, and the strongest adverse factors for prognosis, are the spread of the disease to the regional lymph nodes and formation of distant metastasis. Especially distant extent of the disease significantly reduce treatment options and is associated with poor prognosis. Thus, the biggest future challenges lies in customization of the multidisciplinary treatments, based not only on the clinical assessment of disease advancement determined by stage, but also on the biological factors of the tumor.
Prof. Dr. Pawel Golusinski
Guest Editor
Prof. Dr. Michal Masternak
Co-Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.